Want to see IMMP full AI Analyst Report?
Top Page
Immutep
(NASDAQ:IMMP)
Select Model
Select Model
Rating:43Neutral
Price Target:
$4.50
▲(1084.21% Upside)
Action:Reiterated
Date:09/29/26
The score is weighed down primarily by ongoing large losses and sustained cash burn despite improving revenue and gross margin. Technicals further pressure the score given the strong downtrend and negative momentum (even though the stock appears oversold). Valuation remains constrained by negative earnings and no indicated dividend yield.
Positive Factors
Revenue and gross-margin recovery
The sharp improvement in revenue and gross margin indicates stronger business activity and a more favorable revenue mix. If sustained through clinical and partnering milestones, this progress could improve funding capacity and provide a stronger base for future commercialization.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow means Immutep is consuming capital to maintain development activities rather than funding them internally. Continued deterioration increases the likelihood of additional external financing and limits flexibility if trials or partnerships take longer to mature.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and gross-margin recovery
The sharp improvement in revenue and gross margin indicates stronger business activity and a more favorable revenue mix. If sustained through clinical and partnering milestones, this progress could improve funding capacity and provide a stronger base for future commercialization.
Read all positive factors
Immutep (IMMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.87M
Dividend YieldN/A
Average Volume (3M)20.21K
Price to Earnings (P/E)―
Beta (1Y)2.18
Revenue GrowthN/A
EPS Growth-33.93%
CountryUS
Employees53
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.70
Shares Outstanding7,370,551
10 Day Avg. Volume26,160
30 Day Avg. Volume20,208
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.44
Price to Sales (P/S)6.23
P/FCF Ratio-1.63
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue0.87
Enterprise Value/Gross Profit-0.47
Enterprise Value/Ebitda-0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.97
Revenue Forecast (FY)$2.74M
Immutep Business Overview & Revenue Model
Company Description
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a solu...
How the Company Makes Money
Immutep is a clinical-stage biotech, so its ability to generate recurring product sales depends on successfully developing and commercializing approved therapies; product-revenue detail is null. In the near term, the company’s revenues, when prese...
Immutep Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.24M | 5.04M | 3.84M | 3.51M | 170.37K |
| Gross Profit | 11.82M | -56.37M | -37.70M | 1.44M | -1.89M |
| EBITDA | -79.63M | -62.88M | -44.54M | -39.57M | -31.87M |
| Net Income | -77.57M | -61.43M | -42.72M | -39.90M | -32.21M |
Balance Sheet | |||||
| Total Assets | 83.27M | 156.98M | 201.58M | 147.45M | 102.17M |
| Cash, Cash Equivalents and Short-Term Investments | 68.88M | 129.69M | 181.88M | 123.42M | 80.00M |
| Total Debt | 1.05M | 1.63M | 1.59M | 1.23M | 1.73M |
| Total Liabilities | 21.74M | 13.35M | 12.06M | 10.98M | 8.09M |
| Stockholders Equity | 61.54M | 143.64M | 189.52M | 136.47M | 94.08M |
Cash Flow | |||||
| Free Cash Flow | -54.34M | -62.10M | -35.75M | -35.93M | -30.25M |
| Operating Cash Flow | -54.25M | -62.05M | -34.82M | -35.88M | -30.23M |
| Investing Cash Flow | 55.23M | -38.53M | -21.02M | -31.00K | -22.91K |
| Financing Cash Flow | -209.74K | -525.12K | 95.18M | 76.04M | 50.33M |
Immutep Technical Analysis
Negative
0.38
Price Trends
6.90
Negative
7.62
Negative
22.20
Negative
Market Momentum
-0.78
Positive
19.31
Positive
6.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMMP, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 5.75, below the 50-day MA of 6.90, and below the 200-day MA of 22.20, indicating a bearish trend. The MACD of -0.78 indicates Positive momentum. The RSI at 19.31 is Positive, neither overbought nor oversold. The STOCH value of 6.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMMP.
Immutep Risk Analysis
Immutep disclosed 52 risk factors in its most recent earnings report. Immutep reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immutep Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $661.32M | -2.66 | -106.94% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $222.68M | -1.20 | 141.41% | ― | ― | ― | |
43 Neutral | $32.87M | -0.59 | -98.86% | ― | ― | -33.93% | |
43 Neutral | $226.92M | -0.57 | -91.62% | ― | -55.00% | 51.58% | |
42 Neutral | $101.76M | -2.14 | -94.14% | ― | -0.11% | -13.99% |
* Healthcare Sector Average
IMMP
Immutep
4.27
-34.73
-89.05%
CLLS
Cellectis SA
1.41
-2.12
-60.06%
RNAC
Cartesian Therapeutics
7.14
-2.86
-28.60%
SLN
Silence Therapeutics
10.14
4.95
95.38%
LYEL
Lyell Immunopharma
9.07
-8.78
-49.19%
Immutep Corporate Events
Immutep Resets ADS Ratio to Bolster Nasdaq Listing Compliance
Sep 22, 2026
On September 21, 2026, Immutep detailed a restructuring of its American Depositary Share ratio aimed at supporting its U.S. listing. With effect from the start of Nasdaq trading on September 28, 2026, the ADS ratio will change from one ADS represe...
Immutep Posts Higher FY2026 Loss Despite New Licensing Revenue
Sep 2, 2026
Immutep Limited has released its audited preliminary final report for the year ended 30 June 2026, showing the biotechnology group transition from no reported ordinary revenue in FY2025 to $14.6 million in FY2026, largely from a licensing and coll...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.